1
|
Tavakoli M, Bouzari S, Jafari A, Oloomi M, Asadi Karam MR, Najar-Peerayeh S, Siadat SD. Effect of nontypeable Haemophilus influenzae protein E (PE) as a microbial adjuvant on the amount of antibody against PRP of Haemophilus influenzae type b (Hib) in BALB/c mice. Microb Pathog 2019; 129:78-81. [PMID: 30682526 DOI: 10.1016/j.micpath.2019.01.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 01/15/2019] [Accepted: 01/16/2019] [Indexed: 11/18/2022]
Affiliation(s)
- Minoo Tavakoli
- Biology Department, Science and Research Branch, Islamic Azad University, Tehran, Iran.
| | - Saeid Bouzari
- Molecular Biology Department, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
| | - Anis Jafari
- Molecular Biology Department, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
| | - Mana Oloomi
- Molecular Biology Department, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
| | | | - Shahin Najar-Peerayeh
- Bacteriology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
| | - Seyed Davar Siadat
- Mycobacteriology and Pulmonary Research Department, Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran
| |
Collapse
|
2
|
Thanga Viji V, Deepa K, Velmurugan S, Donio MBS, Adlin Jenifer J, Babu MM, Citarasu T. Vaccination strategies to protect goldfish Carassius auratus against Aeromonas hydrophila infection. DISEASES OF AQUATIC ORGANISMS 2013; 104:45-57. [PMID: 23670079 DOI: 10.3354/dao02581] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Ornamental goldfish Carassius auratus were treated with whole cell (WC), extracellular product (ECP), outer membrane protein (OMP) and biofilm (BF) vaccines developed from the virulent Aeromonas hydrophila (AHV1; GenBank HQ331525.1) with and without the immunoadjuvant Asparagus racemosus. On various days post-vaccination (dpv), the treated fish were challenged with virulent A. hydrophila. These fish were monitored for survival, growth, specific bacterial reduction, and biochemical, haematological and immunological parameters. C. auratus attained 100% mortality within 7 d in non-vaccinated groups, whereas the vaccines helped to significantly (p ≤ 0.001) increase survival after 25 and 50 dpv. The vaccines with immunoadjuvant (ECP₂, OMP₂ and BF₂ treatments) helped to reduce the Aeromonas load after the challenge, and serum albumin, globulin and protein levels were significantly (p < 0.01) improved in the OMP₂- and BF₂-treated groups. Haemoglobin and red blood cell counts were also significantly improved (p < 0.05) in the vaccinated groups compared to the control group. Additionally, haemagglutination occurred at the 1:12 dilution level in the vaccine plus immunoadjuvant-treated groups. Supplementing the vaccines with immunoadjuvant helped to improve phagocytosis to 54.07%, serum bactericidal activity to 14.6% and the albumin:globulin ratio to 7.6% in BF₂ after 50 dpv. Its positive effect significantly (p < 0.05) increased in vaccinated groups compared to controls. Based on the results, especially with the OMP and BF vaccines, the immunoadjuvant A. racemosus helped to improve the efficiency of the vaccines. This approach will aid in the development of more efficient vaccines against bacterial infections affecting the aquaculture industry.
Collapse
Affiliation(s)
- V Thanga Viji
- Centre for Marine Science and Technology, Manonmaniam Sundaranar University Rajakkamangalam, Kanyakumari District, Tamilnadu 629502, India
| | | | | | | | | | | | | |
Collapse
|
3
|
|
4
|
Weiss MM, Weiss PD, Weiss JB. Anthrax vaccine and public health policy. Am J Public Health 2007; 97:1945-51. [PMID: 17901434 PMCID: PMC2040369 DOI: 10.2105/ajph.2006.102749] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2007] [Indexed: 11/04/2022]
Abstract
The Centers for Disease Control and Prevention has classified Bacillus anthracis, the causative organism of anthrax, as a category A potential bioterrorism agent. There are critical shortcomings in the US anthrax vaccine program. Rather than depending on the private sector, the government must assume direct production of anthrax vaccine. The development of a capacity capable of preemptive immunization of the public against anthrax should be considered.
Collapse
|
5
|
Rajput ZI, Hu SH, Xiao CW, Arijo AG. Adjuvant effects of saponins on animal immune responses. J Zhejiang Univ Sci B 2007; 8:153-61. [PMID: 17323426 PMCID: PMC1810383 DOI: 10.1631/jzus.2007.b0153] [Citation(s) in RCA: 138] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2006] [Accepted: 05/26/2006] [Indexed: 11/11/2022]
Abstract
Vaccines require optimal adjuvants including immunopotentiator and delivery systems to offer long term protection from infectious diseases in animals and man. Initially it was believed that adjuvants are responsible for promoting strong and sustainable antibody responses. Now it has been shown that adjuvants influence the isotype and avidity of antibody and also affect the properties of cell-mediated immunity. Mostly oil emulsions, lipopolysaccharides, polymers, saponins, liposomes, cytokines, ISCOMs (immunostimulating complexes), Freund's complete adjuvant, Freund's incomplete adjuvant, alums, bacterial toxins etc., are common adjuvants under investigation. Saponin based adjuvants have the ability to stimulate the cell mediated immune system as well as to enhance antibody production and have the advantage that only a low dose is needed for adjuvant activity. In the present study the importance of adjuvants, their role and the effect of saponin in immune system is reviewed.
Collapse
Affiliation(s)
- Zahid Iqbal Rajput
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310029, China
| | - Song-hua Hu
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310029, China
| | - Chen-wen Xiao
- Department of Veterinary Medicine, College of Animal Sciences, Zhejiang University, Hangzhou 310029, China
| | - Abdullah G. Arijo
- Department of Parasitology, Sindh Agriculture University, Tando Jam 70060, Pakistan
| |
Collapse
|
6
|
Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF. 5-(Dimethoxymethyl)-2'-deoxyuridine: a novel gem diether nucleoside with anti-orthopoxvirus activity. J Med Chem 2006; 49:3377-82. [PMID: 16722657 PMCID: PMC4262926 DOI: 10.1021/jm0601710] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
To provide potential new leads for the treatment of orthopoxvirus infections, the 5-position of the pyrimidine nucleosides have been modified with a gem diether moiety to yield the following new nucleosides: 5-(dimethoxymethyl)-2'-deoxyuridine (2b), 5-(diethoxymethyl)-2'-deoxyuridine (3b), 5-formyl-2'-deoxyuridine ethylene acetal (4b), and 5-formyl-2'-deoxyuridine propylene acetal (5b). These were evaluated in human foreskin fibroblast cells challenged with the vaccinia virus or cowpox virus. Of the four gem diether nucleosides, only the dimethyl gem diether congener showed significant antiviral activity against both viruses. This antiviral activity did not appear to be related to the decomposition to the 5-formyl-2'-deoxyuridine, which was itself devoid of anti-orthopoxvirus activity in these assays. Moreover, at the pH of the in vitro assays, 2b was very stable with a decomposition (to aldehyde) half-life of >15 d. The anti-orthopoxvirus activity of pyrimidine may be favored by the introduction of hydrophilic moieties to the 5-position side chain.
Collapse
Affiliation(s)
| | | | | | | | | | - Paul F. Torrence
- To whom correspondence should be addressed. Tel: (928) 523-0298. Fax: (928) 523-8111.
| |
Collapse
|
7
|
Fan X, Zhang X, Zhou L, Keith KA, Kern ER, Torrence PF. A pyrimidine–pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity. Bioorg Med Chem Lett 2006; 16:3224-8. [PMID: 16603351 DOI: 10.1016/j.bmcl.2006.03.043] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2006] [Revised: 03/13/2006] [Accepted: 03/14/2006] [Indexed: 11/30/2022]
Abstract
Synthetic hybridization of two privileged drug scaffolds, pyrazolone on the one hand and pyrimidine nucleoside on the other, resulted in the generation of two novel 5-substituted pyrimidine nucleosides with potent in vitro antiviral activity against two representative orthopoxviruses, vaccinia virus and cowpox virus.
Collapse
Affiliation(s)
- Xuesen Fan
- Department of Chemistry and Biochemistry, Northern Arizona University, Flagstaff, AZ 86011, USA
| | | | | | | | | | | |
Collapse
|
8
|
Orson FM, Kinsey BM, Densmore CL, Nguyen T, Wu Y, Mbawuike IN, Wyde PR. Protection against influenza infection by cytokine-enhanced aerosol genetic immunization. J Gene Med 2006; 8:488-97. [PMID: 16389596 DOI: 10.1002/jgm.864] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Conventional vaccine development for newly emerging pandemic influenza virus strains would likely take too long to prevent devastating global morbidity and mortality. If DNA vaccines can be distributed and delivered efficiently, genetic immunization could be an attractive solution to this problem, since plasmid DNA is stable, easily engineered to encode new protein antigens, and able to be quickly produced in large quantities. METHODS We compared two novel genetic immunization methods in a mouse model of influenza to evaluate protective effects: aerosol delivery of polyethylenimine (PEI)-complexed hemagglutinin (HA)-expressing plasmid and intravenous (IV) delivery of the plasmid complexed with macroaggregated albumin/PEI. Serial serum samples were obtained for assay of neutralizing antibodies against HA. Mice were then challenged in the airway with influenza virus, and production of infectious virus in the lungs was titered. RESULTS Most mice immunized with HA plasmid alone by aerosol and all mice immunized IV developed protective immune responses, whereas none administered control plasmid were protected. Aerosol co-administration of HA plasmid with plasmids encoding the cytokines interleukin 12 (IL12) and granulocyte-macrophage colony stimulating factor (GM-CSF) markedly increased neutralizing antibody responses, so that all aerosol immunized mice were protected from high level virus proliferation. CONCLUSIONS Cytokine-enhanced aerosol delivery of plasmid vaccines can elicit robust protective immune responses against influenza. Thus, aerosol delivery has the potential to address the need for rapid widespread immunization against new influenza virus strains, and may have applications for other infectious and toxic disease processes.
Collapse
Affiliation(s)
- Frank M Orson
- Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Clostridium botulinum, a Gram-positive, anaerobic spore-forming bacteria, is distinguished by its significant clinical applications as well as its potential to be used as bioterror agent. Growing cells secrete botulinum neurotoxin (BoNT), the most poisonous of all known poisons. While BoNT is the causative agent of deadly neuroparalytic botulism, it also serves as a remarkably effective treatment for involuntary muscle disorders such as blepharospasm, strabismus, hemifacial spasm, certain types of spasticity in children, and other ailments. BoNT is also used in cosmetology for the treatment of glabellar lines, and is well-known as the active component of the anti-aging medications Botox and Dysport. In addition, recent reports show that botulinum neurotoxin can be used as a tool for pharmaceutical drug delivery. However, BoNT remains the deadliest of all toxins, and is viewed by biodefense researchers as a possible agent of bioterrorism (BT). Among seven serotypes, C. botulinum type A is responsible for the highest mortality rate in botulism, and thus has the greatest potential to act as biological weapon. Genome sequencing of C. botulinum type A Hall strain (ATCC 3502) is now complete, and has shown the genome size to be 3.89 Mb with a G+C content of approximately 28.2%. The bacterium harbors a 16.3 kb plasmid with a 26.8% G+C content--slightly lower than that of the chromosome. Most of the virulence factors in C. botulinum are chromosomally encoded; bioinformatic analysis of the genome sequence has shown that the plasmid does not harbor toxin genes or genes for related virulence factors. Interestingly, the plasmid does harbor genes essential to replication, including dnaE, which encodes the alpha subunit of DNA polymerase III which has close similarity with its counterpart in C. perfringens strain 13. The plasmid also contains similar genes to those that encode the ABC-type multidrug transport ATPase, and permease. The presence of ABC-type multidrug transport ATPase, and permease suggests putative involvement of efflux pumps in bacteriocin production, modification, and export in C. botulinum. The C. botulinum plasmid additionally harbors genes for LambdaBa04 prophage and site-specific recombinase that are similar to those found in the Ames strain of Bacillus anthracis; these genes and their products may play a role in genomic rearrangement. Completion of genome sequencing for C. botulinum will provide an opportunity to design genomic and proteomic-based systems for detecting different serotypes of C. botulinum strains in the environment. The completed sequence may also facilitate identification of potential virulence factors and drug targets, as well as help characterize neurotoxin-complexing proteins, their polycistronic expression, and phylogenetic relationships between different serotypes.
Collapse
Affiliation(s)
- H D Shukla
- Center of Marine Biotechnology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21202, USA.
| | | |
Collapse
|
10
|
Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004; 72:2810-6. [PMID: 15102791 PMCID: PMC387897 DOI: 10.1128/iai.72.5.2810-2816.2004] [Citation(s) in RCA: 137] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Vaccination is the most efficient prophylaxis against a variety of infectious diseases. New vaccination strategies rely on the incorporation of effective adjuvants, which stimulate the innate immune response and, in turn, activate the adaptive immune response. It is well established that flagellin induces inflammatory responses through the activation of antigen-presenting cells (APCs). In order to evaluate whether flagellin can serve as a carrier for the development of adjuvants or vaccines, we prepared a flagellin-enhanced green fluorescent protein (EGFP) fusion protein. Our results demonstrate that a flagellin-EGFP fusion protein is capable of stimulating APCs, resulting in the maturation of these cells and secretion of proinflammatory cytokines. Furthermore, APCs pulsed with the flagellin-EGFP fusion protein effectively process and present EGFP antigens. More importantly, animals immunized with the flagellin-EGFP fusion protein developed specific anti-EGFP T-cell responses. In contrast, recombinant EGFP was not able to stimulate APCs, nor did it induce a T-cell response. Thus, recombinant-flagellin fusion proteins may be suitable carriers as adjuvants or vaccines for the development of new vaccination strategies to induce and boost immune responses against infectious diseases and cancer.
Collapse
Affiliation(s)
- Camilo Cuadros
- Sidney Kimmel Cancer Center, San Diego, California 92121, USA
| | | | | | | | | |
Collapse
|
11
|
Hassani M, Patel MC, Pirofski LA. Vaccines for the prevention of diseases caused by potential bioweapons. Clin Immunol 2004; 111:1-15. [PMID: 15093546 DOI: 10.1016/j.clim.2003.09.010] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2003] [Accepted: 09/18/2003] [Indexed: 11/17/2022]
Abstract
The development of vaccines and implementation of vaccination programs are among the most important medical contributions to humanity. To date, vaccination has reduced morbidity and mortality from infectious diseases more than any other specific medical intervention. The intentional use of bioweapons against civilians (bioterrorism), recently highlighted by events around the world, has fueled interest in the development of vaccines for potential microbial agents of bioterror. This review discusses the microbial agents that are considered to pose the greatest risk to the public, the diseases associated with them, and the vaccines that are available for their prevention. The paucity of such vaccines and uncertainty regarding mechanisms of vaccine efficacy and the microbial antigens that elicit protection underscore the need for continued study of host-microbe interaction and the immune response to potential agents of bioterror for the development of new vaccines and immune-based therapies to combat their potential to harm the public.
Collapse
Affiliation(s)
- Morad Hassani
- Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center Bronx NY, 10461 USA
| | | | | |
Collapse
|
12
|
Shelver D, Rajagopal L, Harris TO, Rubens CE. MtaR, a regulator of methionine transport, is critical for survival of group B streptococcus in vivo. J Bacteriol 2003; 185:6592-9. [PMID: 14594832 PMCID: PMC262094 DOI: 10.1128/jb.185.22.6592-6599.2003] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
The group B streptococcus (GBS) is an important human pathogen that infects newborns as well as adults. GBS also provides a model system for studying adaptation to different host environments due to its ability to survive in a variety of sites within the host. In this study, we have characterized a transcription factor, MtaR, that is essential for the ability of GBS to survive in vivo. An isogenic strain bearing a kanamycin insertion in mtaR was attenuated for survival in a neonatal-rat model of sepsis. The mtaR mutant grew poorly in human plasma, suggesting that its utilization of plasma-derived nutrients was inefficient. When an excess of exogenous methionine (200 microg/ml) was provided to the mtaR mutant, its growth rate in plasma was restored to that of the wild-type strain. The mtaR mutant grew poorly in chemically defined medium (CDM) prepared with methionine at a concentration similar to that of plasma (4 microg/ml) but was able to grow normally in CDM prepared with a high concentration of methionine (400 microg/ml). Both the wild-type strain and the mtaR mutant were incapable of growth in CDM lacking methionine, indicating that GBS cannot synthesize methionine de novo. When the abilities of the strains to incorporate radiolabeled methionine were compared, the mtaR mutant incorporated fivefold less methionine than the wild-type strain during a 10-min period. Collectively, the results from this study suggest that the ability to regulate expression of a methionine transport system is critical for GBS survival in vivo.
Collapse
Affiliation(s)
- Daniel Shelver
- Department of Pediatrics, Division of Infectious Disease, Childrens' Hospital and Regional Medical Center and University of Washington, Seattle, Washington 91805, USA
| | | | | | | |
Collapse
|
13
|
Neyts J, De Clercq E. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res 2003; 57:25-33. [PMID: 12615300 DOI: 10.1016/s0166-3542(02)00197-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
The era of antiviral chemotherapy started more than 50 years with the findings by Domagk and his colleagues that thiosemicarbazones showed activity against vaccinia virus. One of the derivatives, methisazone, was even investigated in the prophylaxis of smallpox. With the successful implementation of the smallpox vaccine, the use of methisazone was not further pursued. Should there be a threat of smallpox or other poxvirus infections, that could not be immediately controlled by vaccination, a therapeutic intervention could be envisaged based on several therapeutic strategies targeted at such cellular enzymes as IMP dehydrogenase, SAH hydrolase, OMP decarboxylase and CTP synthetase, as well as viral enzymes such as the DNA polymerase. Most advanced as a therapeutic or early prophylactic modality to tackle poxvirus infection is cidofovir, which was found active (i) in vitro against all poxviruses studied so far; (ii) in vivo, against vaccinia and cowpox virus infections in experimental animal models; as well as (iii) some human poxvirus infections, such as molluscum contagiosum. In case of an inadvertent poxvirus epidemic, antiviral therapy (i.e. with cidofovir) will offer the possibility to provide short-term prophylaxis, or therapy. Cidofovir should also allow to treat severe complications of vaccination as may happen in for example immunosuppressed patients.
Collapse
Affiliation(s)
- Johan Neyts
- Rega Institute for Medical Research, Minderbroedersstraat 10, 3000 Leuven, Belgium.
| | | |
Collapse
|
14
|
Tasota FJ, Henker RA, Hoffman LA. Anthrax as a Biological Weapon: An Old Disease That Poses a New Threat. Crit Care Nurse 2002. [DOI: 10.4037/ccn2002.22.5.21] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- Frederick J. Tasota
- Frederick J. Tasota is a pulmonary clinical specialist who is the project director for the Improving Outcomes in Mechanical Ventilation Grant. He has 23 years of experience in critical care nursing and has written and lectured on a variety of nursing, pulmonary, and critical care topics
- All authors are affiliated with the Department of Acute/Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, Pa
| | - Richard A. Henker
- Richard A. Henker is an associate professor responsible for undergraduate clinical instruction and graduate and undergraduate pathophysiology courses. His research centers on thermoregulation and the inflammatory response
- All authors are affiliated with the Department of Acute/Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, Pa
| | - Leslie A. Hoffman
- Leslie A. Hoffman is professor and chair of the Department of Acute/ Tertiary Care. Her work focuses on finding ways to resolve or minimize dysfunction resulting from pulmonary disease in chronically and critically ill patients
- All authors are affiliated with the Department of Acute/Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, Pa
| |
Collapse
|
15
|
Abstract
Although it is often stated that only vaccination would be able to contain or protect the population against a catastrophic smallpox outbreak, the acyclic nucleoside phosphonate analog cidofovir offers a valuable alternative for the therapy and short-term pre- and post-exposure prophylaxis, not only of smallpox but also of other poxvirus infections and DNA viruses. Cidofovir has proven effective against vaccinia, cowpox and monkeypox in various animal model infections. In cell culture, cidofovir has demonstrated activity against variola virus, the etiological agent of smallpox, and in patients it has shown marked efficacy against molluscum contagiosum and orf, two poxvirus infections. Cidofovir is available as an aqueous solution for intravenous administration and could be reformulated for topical (cream or gel), intranasal (aerosol) or peroral (as a lipid prodrug) use, should the need arise.
Collapse
Affiliation(s)
- Erik De Clercq
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
| |
Collapse
|
16
|
Neyts J, Verbeken E, De Clercq E. Effect of 5-iodo-2'-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother 2002; 46:2842-7. [PMID: 12183236 PMCID: PMC127439 DOI: 10.1128/aac.46.9.2842-2847.2002] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
There is a concern that there may be unregistered stocks of smallpox that can be used for bioterrorism or biological warfare. According to the WHO Advisory Committee on Variola Research, there is a need to develop strategies to treat smallpox infections should they reappear. It would also be important to have an effective drug at hand for the treatment of monkeypox disease in humans. We show here that 5-iodo-2'-deoxyuridine (IDU) is a potent inhibitor of vaccinia virus (VV) replication and that IDU inhibits VV DNA synthesis in a dose-dependent way. The in vivo protective effect of IDU was assessed in the VV tail lesion model in immunocompetent mice and in a lethal model for VV infection in SCID (severe combined immune deficiency) mice that had been infected either intranasally, intraperitoneally, or intravenously. Subcutaneous treatment with IDU at 150 and 100 mg/kg of body weight markedly reduced the number of tail lesions in immunocompetent NMRI mice. Untreated intranasally VV-infected SCID mice died at 20.8 +/- 3.1 days after infection (mean +/- standard deviation). Treatment with IDU (subcutaneously, 150 mg/kg/day [from day 0 to 4] and 75 mg/kg/day [from day 6 to 11]) delayed-virus induced mortality by 15 days (mean day of death +/- standard deviation, 35.8 +/- 6.7; P < 0.0001). This protective effect was associated with (i) an improvement of lung histology and (ii) a marked reduction in lung viral titers. IDU also delayed VV-induced mortality when mice had either been infected intraperitoneally or intravenously. Even when the start of treatment with IDU (in intraperitoneally VV-infected mice) was postponed until 2 or 4 days after infection, an important delay in virus-induced mortality was noted.
Collapse
Affiliation(s)
- Johan Neyts
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, 3000 Leuven, Belgium.
| | | | | |
Collapse
|
17
|
Abstract
Evidence based vaccinology (EBV) is the identification and use of the best evidence in making and implementing decisions during all of the stages of the life of a vaccine, including pre-licensure vaccine development and post-licensure manufacture and research, and utilization of the vaccine for disease control. Vaccines, unlike most pharmaceuticals, are in a continuous process of development both before and after licensure. Changes in biologics manufacturing technology and changes that vaccines induce in population and disease biology lead to periodic review of regimens (and sometimes dosage) based on changing immunologic data or public perceptions relevant to vaccine safety and effectiveness. EBV includes the use of evidence based medicine (EBM) both in clinical trials and in national disease containment programs. The rationale for EBV is that the highest evidentiary standards are required to maintain a rigorous scientific basis of vaccine quality control in manufacture and to ensure valid determination of vaccine efficacy, field effectiveness and safety profiles (including post-licensure safety monitoring), cost-benefit analyses, and risk:benefit ratios. EBV is increasingly based on statistically validated, clearly defined laboratory, manufacturing, clinical and epidemiological research methods and procedures, codified as good laboratory practices (GLP), good manufacturing practices (GMP), good clinical research practices (GCRP) and in clinical and public health practice (good vaccination practices, GVP). Implementation demands many data-driven decisions made by a spectrum of specialists pre- and post-licensure, and is essential to maintaining public confidence in vaccines.
Collapse
Affiliation(s)
- David R Nalin
- Merck Vaccine Division, Merck and Company, P.O. Box 4, WP97A-343, West Point, PA 19486-0004, USA.
| |
Collapse
|
18
|
Timmis KN. Biological land mines: bioterrorism underscores major knowledge deficits in the ecology of infectious agents. Environ Microbiol 2001; 3:741-2. [PMID: 11846767 DOI: 10.1046/j.1462-2920.2001.00260.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|